Key clinical point: Among patients with atrial fibrillation, recent acute coronary syndrome, or percutaneous coronary intervention, and a prior stroke, transient ischemic attack, or thromboembolism, apixaban was a better and safer anticoagulant than warfarin.
Major finding: Prior stroke, transient ischemic attack, or thromboembolism didn’t affect the superior safety and efficacy of apixaban, compared with warfarin.
Study details: A secondary analysis of data from AUGUSTUS, an international study with 4,614 patients enrolled during 2015-2018.
Disclosures: AUGUSTUS was funded by Bristol-Myers Squibb and Pfizer, the companies that jointly market apixaban (Eliquis). Dr. Bahit has received honoraria from Pfizer, and from CSL Behring and Merck. Dr. Elkind and Dr. Goldstein had no relevant disclosures.
Bahit MC et al. ISC 2020,.